Literature DB >> 26667393

Circulating multimarker profile of patients with symptomatic heart failure supports enhanced fibrotic degradation and decreased angiogenesis.

Kevin J Morine1, Vikram Paruchuri1, Xiaoying Qiao1, Najwa Mohammad1, Adam Mcgraw1, Adil Yunis1, Iris Jaffe1, Navin K Kapur1.   

Abstract

BACKGROUND: Heart failure (HF) involves myocardial fibrosis and dysregulated angiogenesis.
OBJECTIVE: We explored whether biomarkers of fibrosis and angiogenesis correlate with HF severity.
METHODS: Biomarkers of fibrosis [procollagen types I and III (PIP and P3NP), carboxyterminal-telopeptide of type I collagen (ICTP), matrix metalloproteases (MMP2 and MMP9), tissue inhibitor of MMP1 (TIMP1)]; and angiogenesis [placental growth factor (PGF), vascular endothelial growth factor (VEGF), soluble Fms-like tyrosine kinase-1 (sFlt1)] were measured in 52 HF patients and 19 controls.
RESULTS: P3NP, ICTP, MMP2, TIMP1, PGF, and sFlt1 levels were elevated in HF, while PIP/ICTP, PGF/sFlt1, and VEGF/sFlt1 ratios were reduced. PIP/ICTP, MMP-9/TIMP1, and VEGF/sFlt1 ratios were lowest among patients with severe HF.
CONCLUSIONS: Severe HF is associated with collagen breakdown and reduced angiogenesis. A multimarker approach may guide therapeutic targeting of fibrosis and angiogenesis in HF.

Entities:  

Keywords:  Cardiovascular disease; growth factors/cytokines/inflammatory mediators; hematology

Mesh:

Substances:

Year:  2015        PMID: 26667393      PMCID: PMC4816665          DOI: 10.3109/1354750X.2015.1118539

Source DB:  PubMed          Journal:  Biomarkers        ISSN: 1354-750X            Impact factor:   2.658


  54 in total

1.  Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients.

Authors:  Javier Díez; Ramón Querejeta; Begoña López; Arantxa González; Mariano Larman; José L Martínez Ubago
Journal:  Circulation       Date:  2002-05-28       Impact factor: 29.690

2.  Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation.

Authors:  J Risteli; I Elomaa; S Niemi; A Novamo; L Risteli
Journal:  Clin Chem       Date:  1993-04       Impact factor: 8.327

3.  Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy.

Authors:  J A Franciosa; M Wilen; S Ziesche; J N Cohn
Journal:  Am J Cardiol       Date:  1983-03-01       Impact factor: 2.778

4.  Circulating C-terminal propeptide of type I procollagen is cleared mainly via the mannose receptor in liver endothelial cells.

Authors:  B Smedsrød; J Melkko; L Risteli; J Risteli
Journal:  Biochem J       Date:  1990-10-15       Impact factor: 3.857

5.  Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis.

Authors:  Ramón Querejeta; Begoña López; Arantxa González; Eloy Sánchez; Mariano Larman; José L Martínez Ubago; Javier Díez
Journal:  Circulation       Date:  2004-08-16       Impact factor: 29.690

6.  Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1.

Authors:  Aernout Luttun; Marc Tjwa; Lieve Moons; Yan Wu; Anne Angelillo-Scherrer; Fang Liao; Janice A Nagy; Andrea Hooper; Josef Priller; Bert De Klerck; Veerle Compernolle; Evis Daci; Peter Bohlen; Mieke Dewerchin; Jean-Marc Herbert; Roy Fava; Patrick Matthys; Geert Carmeliet; Désiré Collen; Harold F Dvorak; Daniel J Hicklin; Peter Carmeliet
Journal:  Nat Med       Date:  2002-07-01       Impact factor: 53.440

7.  Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia.

Authors:  Takeshi Nagamatsu; Tomoyuki Fujii; Maki Kusumi; Li Zou; Takahiro Yamashita; Yutaka Osuga; Mikio Momoeda; Shirou Kozuma; Yuji Taketani
Journal:  Endocrinology       Date:  2004-07-29       Impact factor: 4.736

8.  Serum markers of collagen type I metabolism in spontaneously hypertensive rats: relation to myocardial fibrosis.

Authors:  J Díez; A Panizo; M J Gil; I Monreal; M Hernández; J Pardo Mindán
Journal:  Circulation       Date:  1996-03-01       Impact factor: 29.690

9.  Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis.

Authors:  G Klappacher; P Franzen; D Haab; M Mehrabi; M Binder; K Plesch; R Pacher; M Grimm; I Pribill; H G Eichler
Journal:  Am J Cardiol       Date:  1995-05-01       Impact factor: 2.778

10.  Effect of hypoxia and endothelial loss on vascular smooth muscle cell responsiveness to VEGF-A: role of flt-1/VEGF-receptor-1.

Authors:  Astrid Parenti; Laura Brogelli; Sandra Filippi; Sandra Donnini; Fabrizio Ledda
Journal:  Cardiovasc Res       Date:  2002-07       Impact factor: 10.787

View more
  3 in total

1.  Integrating Pharmacokinetics Study, Network Analysis, and Experimental Validation to Uncover the Mechanism of Qiliqiangxin Capsule Against Chronic Heart Failure.

Authors:  Yu Zhang; Mingdan Zhu; Fugeng Zhang; Shaoqiang Zhang; Wuxun Du; Xuefeng Xiao
Journal:  Front Pharmacol       Date:  2019-09-18       Impact factor: 5.810

2.  Effect of minocycline on the left ventricular function following ST-elevation myocardial infarction treated by primary percutaneous coronary intervention.

Authors:  Alireza Nasiri; Akbar Shafiee; Ali Hosseinsabet; Azita Hajhosein Talasaz; Arash Jalali; Mojtaba Salarifar
Journal:  Trials       Date:  2022-02-04       Impact factor: 2.279

3.  Reduced intracellular chloride concentration impairs angiogenesis by inhibiting oxidative stress-mediated VEGFR2 activation.

Authors:  Kai Li; Ying-Ying Liu; Xiao-Fei Lv; Zhuo-Miao Lin; Ting-Ting Zhang; Fei-Ran Zhang; Jia-Wei Guo; Yu Hong; Xiu Liu; Xiao-Chun Lin; Jia-Guo Zhou; Qian-Qian Wu; Si-Jia Liang; Jin-Yan Shang
Journal:  Acta Pharmacol Sin       Date:  2020-07-21       Impact factor: 6.150

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.